IGC Pharma, Inc.
IGC · AMEX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $21,807 | $28,008 | $17,850 | $47,437 |
| - Cash | $405 | $1,198 | $3,196 | $10,460 |
| + Debt | $238 | $345 | $481 | $488 |
| Enterprise Value | $21,640 | $27,155 | $15,135 | $37,465 |
| Revenue | $1,271 | $1,345 | $911 | $397 |
| % Growth | -5.5% | 47.6% | 129.5% | – |
| Gross Profit | $619 | $733 | -$158 | $194 |
| % Margin | 48.7% | 54.5% | -17.3% | 48.9% |
| EBITDA | -$6,828 | -$9,161 | -$10,849 | -$14,365 |
| % Margin | -537.2% | -681.1% | -1,190.9% | -3,618.4% |
| Net Income | -$7,121 | -$13,000 | -$11,506 | -$15,016 |
| % Margin | -560.3% | -966.5% | -1,263% | -3,782.4% |
| EPS Diluted | -0.093 | -0.22 | -0.22 | -0.3 |
| % Growth | 57.7% | 0% | 26.7% | – |
| Operating Cash Flow | -$4,795 | -$5,199 | -$7,047 | -$7,462 |
| Capital Expenditures | -$482 | -$515 | -$619 | -$771 |
| Free Cash Flow | -$5,277 | -$5,714 | -$7,666 | -$8,233 |